B7-H4 is a potential prognostic biomarker of prostate cancer

Li, Haoyue; Piao, Lihua; Liu, Sicen; Cui, Yan; Xuan, Yanhua

doi:10.1016/j.yexmp.2020.104406

Cited by 16 publications

(8 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the B7-H4 protein is highly expressed in human tumors and is associated with the clinicopathological features of patients ( 157 ). The expression of B7-H4 in gastric ( 169 , 170 ), breast ( 171 , 172 ), lung ( 145 ), prostate ( 173 ), pancreatic ( 174 ), bladder ( 175 ), colorectal ( 176 ), ovarian ( 177 ), renal ( 178 ), urothelial ( 179 ), esophageal ( 180 ), and gallbladder ( 181 ) cancers is associated with tumor size, primary tumor grade, TNM stage, low survival rate, drug resistance and a decreased number of tumor-infiltrating T cells. B7-H4 inhibits the proliferation, cell cycle progression and cytokine production of CD4 + /CD8 + T cells ( 168 , 182 ), attenuates the inflammatory response, and enables tumor cells to evade the immune system ( 132 , 183 ).…”

Section: Significance Of B7-h4 Glycosylationmentioning

confidence: 99%

B7 family protein glycosylation: Promising novel targets in tumor treatment

et al. 2022

View full text Add to dashboard Cite

Cancer immunotherapy, including the inhibition of immune checkpoints, improves the tumor immune microenvironment and is an effective tool for cancer therapy. More effective and alternative inhibitory targets are critical for successful immune checkpoint blockade therapy. The interaction of the immunomodulatory ligand B7 family with corresponding receptors induces or inhibits T cell responses by sending co-stimulatory and co-inhibitory signals respectively. Blocking the glycosylation of the B7 family members PD-L1, PD-L2, B7-H3, and B7-H4 inhibited the self-stability and receptor binding of these immune checkpoint proteins, leading to immunosuppression and rapid tumor progression. Therefore, regulation of glycosylation may be the “golden key” to relieve tumor immunosuppression. The exploration of a more precise glycosylation regulation mechanism and glycan structure of B7 family proteins is conducive to the discovery and clinical application of antibodies and small molecule inhibitors.

show abstract

Section: Significance Of B7-h4 Glycosylationmentioning

confidence: 99%

B7 family protein glycosylation: Promising novel targets in tumor treatment

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Upregulation of VTCN1 has been observed in various tumour tissues, and this is parallel with poor clinical and tumour aggressiveness pathological features [147,148]. In PCa, an elevated level of VTCN1 is associated with activation of genes that establish cancer stem cells (CSC), pathological high tumour stage and poor or shorter OS rate, making it a potential independent prognostic biomarker and therapeutic target [149,150]. CSC, a hallmark of advanced PCa, are a heterogeneous population of tumour cells with the capability for self-renewal, and are associated with increased motility that enables tumour invasion and metastases leading to PCa therapy resistance [151][152][153].…”

Section: V-set Domain-containing T Cell Activation Inhibitor 1 (Vtcn1)mentioning

confidence: 99%

Immune Checkpoints, Inhibitors and Radionuclides in Prostate Cancer: Promising Combinatorial Therapy Approach

Kgatle

Boshomane

Lawal

et al. 2021

IJMS

View full text Add to dashboard Cite

Emerging research demonstrates that co-inhibitory immune checkpoints (ICs) remain the most promising immunotherapy targets in various malignancies. Nonetheless, ICIs have offered insignificant clinical benefits in the treatment of advanced prostate cancer (PCa) especially when they are used as monotherapies. Current existing PCa treatment initially offers an improved clinical outcome and overall survival (OS), however, after a while the treatment becomes resistant leading to aggressive and uncontrolled disease associated with increased mortality and morbidity. Concurrent combination of the ICIs with radionuclides therapy that has rapidly emerged as safe and effective targeted approach for treating PCa patients may shift the paradigm of PCa treatment. Here, we provide an overview of the contextual contribution of old and new emerging inhibitory ICs in PCa, preclinical and clinical studies supporting the use of these ICs in treating PCa patients. Furthermore, we will also describe the potential of using a combinatory approach of ICIs and radionuclides therapy in treating PCa patients to enhance efficacy, durable cancer control and OS. The inhibitory ICs considered in this review are cytotoxic T-lymphocyte antigen 4 (CTLA4), programmed cell death 1 (PD1), V-domain immunoglobulin suppressor of T cell activation (VISTA), indoleamine 2,3-dioxygenase (IDO), T cell Immunoglobulin Domain and Mucin Domain 3 (TIM-3), lymphocyte-activation gene 3 (LAG-3), T cell immunoreceptor with Ig and ITIM domains (TIGIT), B7 homolog 3 (B7-H3) and B7-H4.

show abstract

“…VTCN1 , exhibits est correlation coefficient between methylation and expression, was identified. VTCN1 (a T cell activation suppressor 1), also known as B7-H4, can regulate T cell activation in non-small-cell lung cancer [ 21 ], hepatocellular carcinoma [ 22 ], and prostate cancer [ 23 ]. To further explore whether VTCN1 is involved in regulating the occurrence and development of endometrial cancer through immune factors, we analyzed the level of immune cell infiltration in normal and tumor tissues.…”

Section: Introductionmentioning

confidence: 99%

Integrated Bioinformatic Analysis of DNA Methylation and Immune Infiltration in Endometrial Cancer

Dai

Deng

et al. 2022

BioMed Research International

View full text Add to dashboard Cite

Background. Endometrial cancer greatly threatens the health of female. Emerging evidences have demonstrated that DNA methylation and immune infiltration are involved in the occurrence and development of endometrial cancer. However, the mechanism and prognostic biomarkers of endometrial cancer are still unclear. In this study, we assess DNA methylation and immune infiltration via bioinformatic analysis. Methods. The latest RNA-Seq, DNA methylation data, and clinical data related to endometrial cancer were downloaded from the UCSC Xena dataset. The methylation-driven genes were selected, and then the risk score was obtained using “MethylMix” and “corrplot” R packages. The connection between methylated genes and the expression of screened driven genes were explored using “survminer” and “beeswarm” packages, respectively. Finally, the role of VTCN1in immune infiltration was analyzed using “CIBERSORT” package. Results. In this study, 179 upregulated genes, and 311 downregulated genes were identified and found to be related to extracellular matrix organization, cell–cell junctions, and cell adhesion molecular binding. The methylation-driven gene VTCN1 was selected, and patients classified to the hypomethylation and high expression group displayed poor prognosis. The VTCN1 gene exhibited highest correlation coefficient between methylation and expression. More importantly, the hypomethylation of promoter of VTCN1 led to its high expression, thereby induce tumor development by inhibiting CD8+ T cell infiltration. Conclusions. Overall, our study was the first to reveal the mechanism of endometrial cancer by assessing DNA methylation and immune infiltration via integrated bioinformatic analysis. In addition, we found a pivotal prognostic biomarker for the disease. Our study provides potential targets for the diagnosis and prognosis of endometrial cancer in the future.

show abstract

B7-H4 is a potential prognostic biomarker of prostate cancer

Cited by 16 publications

References 42 publications

B7 family protein glycosylation: Promising novel targets in tumor treatment

B7 family protein glycosylation: Promising novel targets in tumor treatment

Immune Checkpoints, Inhibitors and Radionuclides in Prostate Cancer: Promising Combinatorial Therapy Approach

Integrated Bioinformatic Analysis of DNA Methylation and Immune Infiltration in Endometrial Cancer

Contact Info

Product

Resources

About